Intesa Sanpaolo supports Biofarma Group’s growth in the United States
15 January 2026
Intesa Sanpaolo is supporting the international development of USPL Nutritionals LLC, the US-based company of Biofarma Group, through an international factoring programme of up to €20 million aimed at improving cash flow management and optimising working capital in the US market.
The transaction forms part of Intesa Sanpaolo’s strategy to support investments that foster research, growth and the international consolidation of Italian companies with strong industrial capabilities.
Intesa Sanpaolo’s role in US investments
Intesa Sanpaolo supports SMEs during this phase of global transformation by fostering Italian companies’ investments in research and international growth—particularly in the United States—through specialized advisory services, dedicated financial instruments, and industrial and strategic networking initiatives.
In this framework, Intesa Sanpaolo has organised two missions to Silicon Valley in less than 24 months, involving statrups and SMEs.
Biofarma Group’s global footprint
Biofarma Group is a global Health-Care player with nine manufacturing sites across Europe, America and Asia.
The Group operates exclusively as a contract development and manufacturing organisation, supporting partners across the entire value chain, from R&D to production, regulatory compliance, quality standards and logistics. In 2025, Biofarma Group reported revenues of €443.3 million, with more than 1,500 employees and 190 patents.
Foto credits: courtesy Biofarma
Last updated 15 January 2026 at 16:34:19
